ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of...
ImmunityBio, Inc, a clinical-stage immunotherapy company, announced interim results (N=63) in its metastatic pancreatic cancer trial (QUILT 88) showing that the overall survival rate...
The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania's Gene Therapy Program (GTP) have signed a landmark collaboration agreement, to combine Penn's...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School...
CANbridge Pharmaceuticals Inc., (“CANbridge,” stock code 1228.HK) a leading China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease...
